Compare Illumina, Inc. (ILMN) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JetBlue Airways Corporation — how do they compare? Illumina, Inc. trades at $190.78 (market cap $29.12B), while JetBlue Airways Corporation trades at $5.87 (market cap $2.19B). The key difference: Illumina, Inc. is far larger — about 13.3× JetBlue Airways Corporation's market cap, and Illumina, Inc. is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ILMN | JBLU | |
|---|---|---|
Market Cap | $29.12B | $2.19B |
Sector | Health | Industrials |
52-Week High | $205.10 | $6.46 |
52-Week Low | $91.00 | $4.03 |
Enterprise Value | $30.48B | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
JetBlue (JBLU) trades at $5.64, down 7.08% amid a recent analyst downgrade. The stock shows a bullish technical signal with oversold RSI conditions, but fundamentals reveal persistent losses with a -9.32% net margin and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations, yet revenue trends remain volatile, and cash flow from operations turned negative in 2025. The company is implementing strategic fare changes and targeting 2028 profitability.
The outlook is cautious; while cost initiatives and premium product expansions offer long-term potential, high debt levels, fuel cost pressures, and inconsistent earnings pose significant risks. Analyst consensus is mixed with a hold-heavy rating and a $5.18 price target slightly below the current price, reflecting skepticism about near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
